Clinical Trial Update: 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/2 proof-of-principle trial evaluating AZD2066 for reducing transient lower esophageal sphincter relaxations in patients with gastroe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• AZD2066 (AZD2066)

Snippet

Sponsor: AstraZeneca | Conditions: Reflux Episodes | Phase 1, Phase 2 | Status: COMPLETED